info

Informa Connnect's Pharma/Biotech GTN Summit

Informa Connnect's Pharma/Biotech GTN Summit
November 18-20, 2024 | W Philadelphia Hotel, Philadelphia, PA
Drug Channels Readers Receive 15% Off* with Code 24DGC15.

View the Complete Agenda

Book Your Place

The complex components of gross-to-net management requires cross-functional collaboration in order to effectively develop sound accrual estimates, proper forecasting, optimized pricing and contracting models and accurate financial reporting, all with minimal disruption to market access strategies.

The CPE-accredited Pharma/Biotech GTN Summit is the ideal opportunity to engage in comprehensive sessions for end-to-end GTN excellence, connect with peers to exchange experiences and solutions to common challenges, and participate in interactive discussions that address real-world scenarios to enhance GTN accuracy and efficiency.

Featured Thought-Leaders Leading the Dialogue Include:
  • Nancy Bell, Vice President, Head of US Patient Value & Access, Takeda Oncology
  • Chris Boneham, Vice President, Market Access US, Y-mAbs Therapeutics
  • Prakash Chainani, Vice President – Finance, HR & IT, Lifestar Pharma LLC (a Mankind Group Company)
  • George Kappus, Associate Director, M&S Controlling (GtN, Boehringer Ingelheim
  • Sherri Cirota, Executive Director, Contracts & Pricing, Alkermes
  • Chris Rocco, Senior Director, Market Access Data, Reporting & Analytics, GSK
  • Rosalind Davis, Director, Government Pricing & Contracts, CSL Vifor
  • Dan Sacchetta, Director Managed Markets Finance- Gross-to-Net, Novartis
  • Eckart Beuttenmueller, Director, Gross-to-Net Execution, Bayer
  • Kinneret Klein, Executive Director, Commercial Financial Planning & Analysis, Biocryst
  • James Engel, Controller, Finance, Collegium Pharmaceuticals
  • Brett Nussbaum, Head of Gross to Net Accounting, Novartis
  • Timothy Kocses, Executive Director, US Commercial Controller, Bristol Myers Squibb
  • Robert Lucchesi, Director, FP&A Sales Reporting & Forecasting, Novo Nordisk
  • Funso Olufade, PhD, MBA, Sr. Director – Head, Commercial Finance, Ascendis Pharma
  • Amy Ramazio, Contract Forecasting & Analytics Director, GSK US Market Access
  • Ranish Singhvi, Vice President, Finance, Accord Healthcare
  • Jeffrey Miller, Assistant Vice President & Corporate Controller, Lannett Company
  • Bal Ram, SVP Finance, US Operations, Indivior
  • Matthew Pellegrini, Sr. Director - Revenue Optimization Contracting & Compliance N.A, Teva Pharmaceuticals
  • Michael Domanico, Vice President Finance, Revenue, Sandoz
  • Christopher Wang, Corporate Controller, Revance Therapeutics
  • Melissa Norton, Assistant Controller, Revenue, Tolmar
  • Michael Christiano, Director, Revenue, Ardelyx
Learn more and see why the GTN Summit remains a great choice for education and benchmarking on strategic forecasting, estimates, analytics and reporting through best practices for gross-to-net management.

Drug Channels subscribers — Save 15% when you reserve your place using the VIP code 24DGC15.

*Offer applies to the current rate and maybe not be applied to existing registrations; additional terms may apply, see website for full details.


The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).
       




info

Informa Connect's Copay, Reimbursement and Access Congress

Informa Connect's Copay, Reimbursement and Access Congress
November 18-20, 2024 | Hilton Penn’s Landing in Philadelphia, PA
Drug Channels readers save 10% with code USAVE24*

The access and affordability landscape is undergoing a seismic shift. Evolving legislation, disruptive market forces and the ever-growing complexities of cost sharing programs threaten patient adherence and commercialization strategies. Are you ready?

A program driven by marketplace insights and led by industry trailblazers, Copay, Reimbursement and Access Congress is back November 18-20 and will deliver up-to-date insights necessary to enhance patient affordability, ensure program sustainability and navigate the regulatory landscape. In a time where remaining compliant has never been more complex and program innovation has never been more important, be sure to join your industry counterparts to drive adherence, access and commercialization forward.

Why attend the Copay, Reimbursement and Access Congress?

Keeping up with shifting market dynamics in the midst of maximizing access, while also meeting business objectives is a challenging task and brings about many questions for access professionals.
  • Is your program sustainable and innovative to better support patients?
  • Accumulators, maximizers, AFPs – What are your next steps to ensure effective reimbursement strategies?
  • In an election year, what is the future of health policy?
Experts will tackle these questions and more as the industry comes together to benchmark best practices to accelerate access and commercialization. Do not miss your chance to join seasoned leaders, your peers and leading solution providers as they navigate marketplace trends and dive into the impact coupons, benefit design, accumulators, maximizers, alternative funding programs and drug pricing legislation have on patient affordability and out-of-pocket costs. This is your chance to gain critical insights on industry standards, forward-thinking strategies to optimize your copay and cost sharing programs and so much more.

Content highlights:
  • Over 20 hours of content, including 7+ dedicated sessions to help decipher copay legislation
  • Crucial perspectives from Pfizer, Sanofi, Janssen, Teva, Ascendis Pharma, Melinta Therapeutics, GSK, HIV + Hepatitis Policy Institute and more
  • Insights direct from enforcement agents on the top trends and actions within the copay and patient services space
  • Illuminating case study, Navigating the Patient Journey in a Shifting Copay Landscape from Spark Therapeutics
  • 465 minutes of valuable in-person networking with colleagues and counterparts to expand your network and establish powerful partnerships
  • Additional content access through Streamly, a platform that gives you 12-month access to all of the available conference content** to review at your leisure
  • And more!
Download the agenda and register today—Be sure to use your exclusive promo USAVE24 to save 10% off* of your registration

See you there!

*Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.
**Pending speaker permissions



The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).

       




info

Informa Connect’s PBM Contracting Summit

Informa Connect’s PBM Contracting Summit
December 10-11, 2024 | Chicago, IL
Drug Channels readers save 10% with code 24DRCH10*

Experts from across the US come together each year at the PBM Contracting Summit to gain innovative and practical contracting strategies, master PBM innovation and design, improve patient care management and rising costs, understand the current legislative issues impacting contract negotiations and more. Join us in Chicago (or virtually) where you’ll benefit from two days of learning, education and networking, and will return to the office having mastered the complex PBM landscape.

You’ll hear from Matthew Gibbs, Pharm.D., Pharmacy Transformation Leader of Blue Shield of California as he leads a comprehensive discussion on the PBM landscape over the last year, and delves into the evolving trends and emerging challenges shaping the current industry today.

Other expert and thought leaders from within the industry are slated to present deep dive sessions, workshops and panels that will answer your most pressing questions:
  • What are the latest legislative updates and proposed federal bills impacting PBM operations?
  • What's on the horizon for alternative PBMs? What are the top intricacies of rebate eligibility? What are the market impacts of innovative models such as Mark Cuban's Cost Plus Drugs and Amazon's pharmacy model?
  • What can be learned from the J&J lawsuit? Review the expansion of data access and the importance of employer's fiduciary duties.
  • What are the challenges of vertical integration?
  • How do PBMs manage their contracting processes with plan sponsors to create successful contracts?
  • What are the most effective strategies for spread pricing and reimbursement models?
  • What is the best solution to navigate the challenges of the 340B drug pricing program and PBM contracting?
  • What is the best way to design and optimize benefits for covering GLP-1s?
  • How can I ensure compliance with ERISA requirements?
  • What are the latest developments in copay maximizer and accumulator programs?
  • What market dynamics and barriers are impacting pricing and demand?
  • What can be learned from the economic landscape of biosimilars and specialty therapeutics?
  • And much more!

View the agenda for the PBM Contracting Summit to see the complete picture – the program, speakers, and more, visit www.informaconnect.com/pbm-contracting for further details and to register. Drug Channels readers will save 10% off when they use code 24DRCH10 and register prior to November 8, 2024.*

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates or other offers. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).
       




info

Informa Connect’s Trade and Channel Strategies

Informa Connect’s Trade and Channel Strategies
December 10-12, 2024 at the W Hotel in Philadelphia, PA
Drug Channels readers save 10% with code 24DC10*

Pharmacy and distribution models are growing increasingly complex. Stop running in circles—It’s time to unlock proven strategies to propel market access.

What is the secret to success? Trade and Channel Strategies is bringing together industry experts to deliver specific strategies and talk best practices in tackling the latest industry challenges.

As the landscape rapidly evolves, there are only two choices—Adapt or risk falling behind. With policy changes and market fluctuations, specifically surrounding the DSCSA and IRA, the loss of exclusivity wave, adoption of low-WAC products affecting GTN and the rise of innovations within the pharmacy sector, there has never been a more important time for industry to unite. A program driven by market dynamics and led by champions of channel strategy, join your peers now to master the complexities of pharmacy and distribution models to accelerate market access—It's all happening December 10-12.

Why do trade and channel professionals choose this pivotal event?

The challenge of staying viable among shifting market dynamics while meeting business objectives is heavy. Professionals are left with many questions, including:
  • How will the new administration affect the distribution channel?
  • Is my organization haemorrhaging money to stay afloat with the shift to alternative distribution and pharmacy models?
  • Does the DSCSA deadline change affect my organization? Am I still prepared?
Join the experts for three dedicated days of collaborative discussions that will give you the answers to these questions and so many more. Leaders in the landscape are uniting and will dive into the top trends for innovative distribution, integrated pharmacy models and talk the truth about the future of trade.

WHAT CAN YOU EXPECT?

Vital insights from industry’s leading pharmacy and distribution experts, including:
  • Bill Roth, Senior Vice President of Consulting, Blue Fin Group, An IntegriChain Company
  • Patrick Lupo Group Vice President, Pharmacy Trade and Specialty, Walgreens
  • Amanda Salindong, Associate Director, Channel & Distribution, Alnylam Pharmaceuticals
  • Chris Rocco, Senior Director, Market Access Data, Reporting & Analytics, GSK
  • Eliane Maalouf, Director Trade and Fulfillment, Mass General Brigham Specialty Pharmacy
  • Stephanie Wirkes, Head of Distribution and Strategy Execution, Bayer
  • John Harlow, Chief Commercial Officer, Melinta Therapeutics
  • Aria Cohen, Vice President, Head of Market Access, Alkeus Pharmaceuticals, Inc.
  • Elizabeth Cherry, Program Director for Trade Relations, Vanderbilt Specialty Pharmacy
  • Danielle Bryan, PharmD, CSP, Program Director, Specialty Pharmacy Trade Relations, Vanderbilt University Medical Center
  • Thomas Scalone, Director, Trade Strategy and Operations, Bristol Myers Squibb
  • Dina Lynch, VP, Market Access and Reimbursement, Renibus Therapeutics
  • And more!
Tackle the hottest topics facing industry right now, including:
  • Keynote Address: Access and Channel 2024 In-Review and Preview of 2025
  • Pharmacy Evolved—Aligning Commercialization to the Changing Pharmacy Channel
  • Advanced Trade Leaders Executive Session
  • Navigate and Operationalize the IRA
  • Focused Multi-Track Offerings:
    • Supply Chain, Distribution and Logistics
    • Pharmacy Models and Reimbursement Strategies
    • Data, Innovation and Analytics
    • Health Systems and Pharma Partnering Symposium
  • Balancing the GTN Bubble with Market Access Priorities
  • What’s Happening in Retail—Brick and Morter, Home Delivery and Cash Pay Pharmacies
  • Navigating Post Deadline Challenges—DSCSA Compliance and Serialization Updates
  • Four Roundtable Breakout Discussions:
    • What Good Looks Like in a 3PL/Manufacturer Partnership
    • Optimizing Healthcare Partnerships
    • Women in Trade
    • GLP-1s and New Product Archetypes
  • Actions Needed to Mitigate and Prevent Drug Shortages
  • Case Study: Master Your Organization Chart—Ensuring Higher Cross Functional Interactions
  • Three Interactive Workshops:
    • Trade 101
    • Advanced Trade Leaders Executive Session
    • Health Systems Fundamentals
  • And more!
Exclusive Offer—Download the agenda and register today—Be sure to use your exclusive promo 24DC10 to save 10% off* of your registration.

See you there!

* Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).
       




info

Waiver of Informed Consent - proposed changes in the 21st Century Cures Act

Adam Feuerstein points out - and expresses considerable alarm over - an overlooked clause in the 21st Century Cures Act:


In another tweet, he suggests that the act will "decimate" informed consent in drug trials. Subsequent responses and retweets  did nothing to clarify the situation, and if anything tended to spread, rather than address, Feuerstein's confusion.

Below is a quick recap of the current regulatory context and a real-life example of where the new wording may be helpful. In short, though, I think it's safe to say:


  1. Waiving informed consent is not new; it's already permitted under current regs
  2. The standards for obtaining a waiver of consent are stringent
  3. They may, in fact, be too stringent in a small number of situations
  4. The act may, in fact, be helpful in those situations
  5. Feuerstein may, in fact, need to chill out a little bit


(For the purposes of this discussion, I’m talking about drug trials, but I believe the device trial situation is parallel.)

Section 505(i) - the section this act proposes to amend - instructs the Secretary of Health and Human Services to propagate rules regarding clinical research. Subsection 4 addresses informed consent:

…the manufacturer, or the sponsor of the investigation, require[e] that experts using such drugs for investigational purposes certify to such manufacturer or sponsor that they will inform any human beings to whom such drugs, or any controls used in connection therewith, are being administered, or their representatives, that such drugs are being used for investigational purposes and will obtain the consent of such human beings or their representatives, except where it is not feasible or it is contrary to the best interests of such human beings.

[emphasis  mine]

Note that this section already recognizes situations where informed consent may be waived for practical or ethical reasons.

These rules were in fact promulgated under 45 CFR part 46, section 116. The relevant bit – as far as this conversation goes – regards circumstances under which informed consent might be fully or partially waived. Specifically, there are 4 criteria, all of which need to be met:

 (1) The research involves no more than minimal risk to the subjects;
 (2) The waiver or alteration will not adversely affect the rights and welfare of the subjects;
 (3) The research could not practicably be carried out without the waiver or alteration; and
 (4) Whenever appropriate, the subjects will be provided with additional pertinent information after participation.

In practice, this is an especially difficult set of criteria to meet for most studies. Criterion (1) rules out most “conventional” clinical trials, because the hallmarks of those trials (use of an investigational medicine, randomization of treatment, blinding of treatment allocation) are all deemed to be more than “minimal risk”. That leaves observational studies – but even many of these cannot clear the bar of criterion (3).

That word “practicably” is a doozy.

Here’s an all-too-real example from recent personal experience. A drug manufacturer wants to understand physicians’ rationales for performing a certain procedure. It seems – but there is little hard data – that a lot of physicians do not strictly follow guidelines on when to perform the procedure. So we devise a study: whenever the procedure is performed, we ask the physician to complete a quick form categorizing why they made their decision. We also ask him or her to transcribe a few pieces of data from the patient chart.

Even though the patients aren’t personally identifiable, the collection of medical data qualifies this as a clinical trial.

It’s a minimal risk trial, definitely: the trial doesn’t dictate at all what the doctor should do, it just asks him or her to record what they did and why, and supply a bit of medical context for the decision. All told, we estimated 15 minutes of physician time to complete the form.

The IRB monitoring the trial, however, denied our request for a waiver of informed consent, since it was “practicable” (not easy, but possible) to obtain informed consent from the patient.  Informed consent – even with a slimmed-down form – was going to take a minimum of 30 minutes, so the length of the physician’s involvement tripled. In addition, many physicians opted out of the trial because they felt that the informed consent process added unnecessary anxiety and alarm for their patients, and provided no corresponding benefit.

The end result was not surprising: the budget for the trial more than doubled, and enrollment was far below expectations.

Which leads to two questions:

1.       Did the informed consent appreciably help a single patient in the trial? Very arguably, no. Consenting to being “in” the trial made zero difference in the patients’ care, added time to their stay in the clinic, and possibly added to their anxiety.
2.       Was less knowledge collected as a result? Absolutely, yes. The sponsor could have run two studies for the same cost. Instead, they ultimately reduced the power of the trial in order to cut losses.


Bottom line, it appears that the modifications proposed in the 21st Century Cures Act really only targets trials like the one in the example. The language clearly retains criteria 1 and 2 of the current HHS regs, which are the most important from a patient safety perspective, but cuts down the “practicability” requirement, potentially permitting high quality studies to be run with less time and cost.

Ultimately, it looks like a very small, but positive, change to the current rules.

The rest of the act appears to be a mash-up of some very good and some very bad (or at least not fully thought out) ideas. However, this clause should not be cause for alarm.




info

Is AI Search a Medical Misinformation Disaster?



Last month when Google introduced its new AI search tool, called AI Overviews, the company seemed confident that it had tested the tool sufficiently, noting in the announcement that “people have already used AI Overviews billions of times through our experiment in Search Labs.” The tool doesn’t just return links to Web pages, as in a typical Google search, but returns an answer that it has generated based on various sources, which it links to below the answer. But immediately after the launch users began posting examples of extremely wrong answers, including a pizza recipe that included glue and the interesting fact that a dog has played in the NBA.

Renée DiResta has been tracking online misinformation for many years as the technical research manager at Stanford’s Internet Observatory.

While the pizza recipe is unlikely to convince anyone to squeeze on the Elmer’s, not all of AI Overview’s extremely wrong answers are so obvious—and some have the potential to be quite harmful. Renée DiResta has been tracking online misinformation for many years as the technical research manager at Stanford’s Internet Observatory and has a new book out about the online propagandists who “turn lies into reality.” She has studied the spread of medical misinformation via social media, so IEEE Spectrum spoke to her about whether AI search is likely to bring an onslaught of erroneous medical advice to unwary users.

I know you’ve been tracking disinformation on the Web for many years. Do you expect the introduction of AI-augmented search tools like Google’s AI Overviews to make the situation worse or better?

Renée DiResta: It’s a really interesting question. There are a couple of policies that Google has had in place for a long time that appear to be in tension with what’s coming out of AI-generated search. That’s made me feel like part of this is Google trying to keep up with where the market has gone. There’s been an incredible acceleration in the release of generative AI tools, and we are seeing Big Tech incumbents trying to make sure that they stay competitive. I think that’s one of the things that’s happening here.

We have long known that hallucinations are a thing that happens with large language models. That’s not new. It’s the deployment of them in a search capacity that I think has been rushed and ill-considered because people expect search engines to give them authoritative information. That’s the expectation you have on search, whereas you might not have that expectation on social media.

There are plenty of examples of comically poor results from AI search, things like how many rocks we should eat per day [a response that was drawn for an Onion article]. But I’m wondering if we should be worried about more serious medical misinformation. I came across one blog post about Google’s AI Overviews responses about stem-cell treatments. The problem there seemed to be that the AI search tool was sourcing its answers from disreputable clinics that were offering unproven treatments. Have you seen other examples of that kind of thing?

DiResta: I have. It’s returning information synthesized from the data that it’s trained on. The problem is that it does not seem to be adhering to the same standards that have long gone into how Google thinks about returning search results for health information. So what I mean by that is Google has, for upwards of 10 years at this point, had a search policy called Your Money or Your Life. Are you familiar with that?

I don’t think so.

DiResta: Your Money or Your Life acknowledges that for queries related to finance and health, Google has a responsibility to hold search results to a very high standard of care, and it’s paramount to get the information correct. People are coming to Google with sensitive questions and they’re looking for information to make materially impactful decisions about their lives. They’re not there for entertainment when they’re asking a question about how to respond to a new cancer diagnosis, for example, or what sort of retirement plan they should be subscribing to. So you don’t want content farms and random Reddit posts and garbage to be the results that are returned. You want to have reputable search results.

That framework of Your Money or Your Life has informed Google’s work on these high-stakes topics for quite some time. And that’s why I think it’s disturbing for people to see the AI-generated search results regurgitating clearly wrong health information from low-quality sites that perhaps happened to be in the training data.

So it seems like AI overviews is not following that same policy—or that’s what it appears like from the outside?

DiResta: That’s how it appears from the outside. I don’t know how they’re thinking about it internally. But those screenshots you’re seeing—a lot of these instances are being traced back to an isolated social media post or a clinic that’s disreputable but exists—are out there on the Internet. It’s not simply making things up. But it’s also not returning what we would consider to be a high-quality result in formulating its response.

I saw that Google responded to some of the problems with a blog post saying that it is aware of these poor results and it’s trying to make improvements. And I can read you the one bullet point that addressed health. It said, “For topics like news and health, we already have strong guardrails in place. In the case of health, we launched additional triggering refinements to enhance our quality protections.” Do you know what that means?

DiResta: That blog posts is an explanation that [AI Overviews] isn’t simply hallucinating—the fact that it’s pointing to URLs is supposed to be a guardrail because that enables the user to go and follow the result to its source. This is a good thing. They should be including those sources for transparency and so that outsiders can review them. However, it is also a fair bit of onus to put on the audience, given the trust that Google has built up over time by returning high-quality results in its health information search rankings.

I know one topic that you’ve tracked over the years has been disinformation about vaccine safety. Have you seen any evidence of that kind of disinformation making its way into AI search?

DiResta: I haven’t, though I imagine outside research teams are now testing results to see what appears. Vaccines have been so much a focus of the conversation around health misinformation for quite some time, I imagine that Google has had people looking specifically at that topic in internal reviews, whereas some of these other topics might be less in the forefront of the minds of the quality teams that are tasked with checking if there are bad results being returned.

What do you think Google’s next moves should be to prevent medical misinformation in AI search?

DiResta: Google has a perfectly good policy to pursue. Your Money or Your Life is a solid ethical guideline to incorporate into this manifestation of the future of search. So it’s not that I think there’s a new and novel ethical grounding that needs to happen. I think it’s more ensuring that the ethical grounding that exists remains foundational to the new AI search tools.




info

Do People Believe Misinformation on Vaccines?

Social media has become a significant source of health-related content. But while it connects people to news, updates, […]

The post Do People Believe Misinformation on Vaccines? appeared first on World of DTC Marketing.



  • As I See It
  • Focus on patients
  • Health information online
  • Misinformation on vaccines

info

185384: Menon says India to decide on information-sharing with Pakistan

Menon emphasized that India had been tough on Pakistan with regard to accountability, but restrained in its rhetoric and actions.




info

221726: Indian information inadequate to warrant listing of three Pakistan-based individuals

Chinese officials had approached the Indian government for more information but had since been reportedly told by the Indian government that the information presented was sufficient to justify the listing.






info

Circulation de l�information transatlantique: comment s�assurer que les investisseurs am�ricains ne voient pas d��crans vides - Trans-Atlantic Information Flow

Trans-Atlantic Information Flow




info

Actor/Comedian Rob Riggle Joins Easter Seals Dixon Center to Reinforce Value of Employing Veterans - What to Wear

Rob Riggle Stars alongside Brice Williams in the newest Easter Seals Dixon Center PSA, directed by Jim Fabio with support from Judd Apatow




info

61% of Mobile Workers Trust Their Employer to Keep Personal Information Private on Their Mobile Devices - What can employers see on smartphones

Smartphones hold increasing amounts of sensitive personal data, so every device is now a mixed-use device. As a result, businesses must protect employee privacy as fiercely as corporate security.





info

New Program Informs Teachers' Ethical Decision Making - ProEthica� Training Program

New program offers educators techniques and strategies for improving awareness of professional risks and vulnerabilities, and for the application of professional ethics in daily decision making.




info

Informe reciente resalta la necesidad de concentrarse más en que las familias planifiquen para estar preparadas - Waiting 30 Seconds Spanish

Waiting 30 Seconds Spanish





info

WINTERKEEP Virtual Tour Info

 Hi, everyone. In the midst of all this difficult news, Winterkeep is about to be released. So it's time to share the dates and details of my virtual tour events. If you're looking for a happy escape from all that's going on — and let's face it, probably some conversation about how books help us absorb/understand/frame current events — please join us! I'm going to be talking to a lot of super interesting people: Author and podcaster Sarah Enni. Authors Malinda Lo and Tui Sutherland. Agent Faye Bender and editor Andrew Karre.

Here's a link to my tour page: http://www.penguinteen.com/event/kristin-cashore-on-tour/

 

And I'll also spell everything out here:

First up, on Tuesday, January 19 at 7PM ET, I’ll be in conversation with Sarah Enni, hosted by the Brookline Booksmith. Sarah’s an author and journalist who’s the host of the wonderful First Draft podcast. More details and registration here: https://www.brooklinebooksmith.com/event/kristin-cashore-sarah-enni.

Next, on Sunday, January 24 at 2PM PST (5PM EST), Malinda Lo & I will talk about Winterkeep and Malinda’s beautiful new release, Last Night at the Telegraph Club. Our conversation will be moderated by Wings of Fire author Tui Sutherland. You can probably expect some craft talk! This event is hosted by Mysterious Galaxy. Details and registration here: https://www.mystgalaxy.com/cashorelo124 

Finally, on Monday, January 25 at 6PM EST, I’ll be in conversation with agent Faye Bender, hosted by editor Andrew Karre. Certainly some publishing talk! This event is hosted by Books & Books. Details and registration here:  https://booksandbooks.com/event/winterkeep-an-evening-with-kristin-cashore/ 

All events can be attended virtually for free. If you're purchasing a book as part of your registration, limited signatures and personalizations are available in some cases, so please do check the details.

And thanks.







info

"The Misinformation Web": Maria Hinojosa on the Pro-Trump Propaganda Targeting Latinos in 2024

As Latino voters are a key voting bloc in the 2024 presidential election in battleground states like Nevada, Arizona and Pennsylvania, they have been targeted by a rise in Spanish-language misinformation. Most of the false messaging disparages Kamala Harris and supports Donald Trump, says Pulitzer Prize-winning journalist Maria Hinojosa, host of Latino USA, which investigated the phenomenon in a new episode called “The Misinformation Web.” She interviewed some of the content creators in this “blob” of online vitriol and says there is almost no effective content moderation online, nor many reliable fact-checking sources in Spanish to counter the lies.




info

Science needs specific, informed, productive criticism

Professor Dave demolishes Sabine Hossenfelder. I feel that. The topic of my history class last week and this week is about bias in late 19th/early 20th century evolutionary biology, and how we have to be critical and responsible in our assessment of scientific claims. It’s tough, because I’m strongly pro-science (obviously, I hope?) but I […]




info

How X users can earn thousands from US election misinformation and AI images

The accounts are part of pro-Trump and pro-Harris networks sharing each other’s content multiple times a day.




info

AI Chatbots: A Risky Source for Drug Information?

Patients should be cautious when relying solely on AI-powered search engines and chatbots for drug information, warn researchers in the journal iBMJ Quality (and) Safety.




info

Major WHO Report is Informed by Eye Care Research.

New research published today in The Lancet Global Health reveals that less than half of people over 50 worldwide have received spectacles or contact lenses




info

Sri Lankan water history informs global climate change study

Modern farming practice of rainwater storage in ancient tanks lauded as best practice adaptation strategy Bonn, Germany. 14 JUNE 2013 —Whether it’s bracing for drought in Sri Lanka with a return to ancient water storage systems or swapping coffee for cocoa in Central America, findings from a new report from the CGIAR Research Program on Climate […]

The post Sri Lankan water history informs global climate change study first appeared on International Water Management Institute (IWMI).




info

President Rajapaksa launches new water information system during visit to IWMI

17th January 2014 – Colombo, Sri Lanka – His Excellency Mahinda Rajapaksa, President of the Democratic Socialist Republic of Sri Lanka, has officially launched a new, hi-tech information system that promises to enhance water management in the South Asian country. Download the full media release

The post President Rajapaksa launches new water information system during visit to IWMI first appeared on International Water Management Institute (IWMI).




info

Application with Geo-Goviya information system launched

The new application, supported by IWMI, includes information about Sri Lanka’s land use, quantity of paddy land, number of farmers, land cultivated in one season and available yield, and emergency agricultural information.

The post Application with Geo-Goviya information system launched first appeared on International Water Management Institute (IWMI).



  • In the media

info

Empowering India's Informal Sector Workers with HIV and TB Care

The Ministry of Labour and Employment reports that a staggering 93% of India's workforce operates in the informal sector. Many of these workers, including




info

FDA CONSUMER HEALTH INFORMATION - FDA's MedWatch Safety Alerts: April 2010

FDA CONSUMER HEALTH INFORMATION - FDA's MedWatch Safety Alerts: April 2010




info

TikTok Provides Misinformation on Sexual Education to Adolescents

Teenagers and young adults rely on TikTok for information. However, a new study reveals that TikTok provides misinformation on sexual education. The




info

Tips on how to Inform That you Have Too many Toxins with the Physique ?

Full Article



info

Make Google a 'trusted source of information' in US election: Sundar Pichai to employees

Sundar Pichai stressed to employees that Google's products must be a trusted info source for all, amid White House vote counting.




info

Vinod Khosla calls out Trump’s ‘depraved values’ and Musk’s role in spreading misinformation

Storied investor Vinod Khosla, founder and partner at Khosla Ventures, and more recently one of the first checks into OpenAI, veered off topic during a Monday interview at TechCrunch Disrupt 2024 focused on the future of AI. After talking about AI’s future and risks, he took a moment to deliver a stringent warning about the […]

© 2024 TechCrunch. All rights reserved. For personal use only.




info

‘For You’ feeds fail on election night, offering outdated information, angering users

“For You” algorithms that promote the most interesting content across a social network, personalized to the individual user, offered a disjointed, outdated, and nearly unusable experience on election night in the U.S. as they highlighted hours-old posts that no longer reflected the current state of the race. Frustrations were particularly high on Threads, Meta’s X […]

© 2024 TechCrunch. All rights reserved. For personal use only.




info

Information Technology Specialist (APPSW) - GS-14

Announcement Number: TN-19-EI-00850-DE
Closing Date: 20 November 2018




info

Information Technology Specialist (APPSW) - GS-14

Announcement Number: SE-18-EI-00814-MP
Closing Date: 15 August 2018




info

Information Technology Specialist (APPSW) - GS-14

Announcement Number: SE-18-EI-00824-MP
Closing Date: 13 August 2018




info

Information Technology Specialist (APPSW) - GS-14

Announcement Number: SE-18-EI-00814-DE
Closing Date: 15 August 2018




info

Information Technology Specialist (APPSW) - GS-14

Announcement Number: TN-19-EI-00850-MP
Closing Date: 20 November 2018




info

Information Technology Specialist (APPSW) - GS-14

Announcement Number: SE-18-EI-00824-DE
Closing Date: 13 August 2018




info

Information Technology Specialist (ENTARCH) - GS-15

Announcement Number: TN-19-EI-00855-DE
Closing Date: 01 February 2019




info

Information Technology Specialist (ENTARCH) - GS-15

Announcement Number: SE-18-EI-00805-MP
Closing Date: 09 April 2018




info

Information Technology Specialist (ENTARCH) - GS-15

Announcement Number: SE-18-EI-00822-DE
Closing Date: 20 September 2018




info

Information Technology Specialist (ENTARCH) - GS-14

Announcement Number: TN-19-EI-00852-MP
Closing Date: 27 November 2018




info

Information Technology Specialist (ENTARCH) - GS-15

Announcement Number: TN-19-EI-00855-MP
Closing Date: 01 February 2019




info

Information Technology Specialist (ENTARCH) - GS-14

Announcement Number: TN-19-EI-00852-DE
Closing Date: 27 November 2018




info

Information Technology Specialist (ENTARCH) - GS-15

Announcement Number: SE-18-EI-00822-MP
Closing Date: 20 September 2018




info

Information Technology Specialist (ENTARCH) - GS-14

Announcement Number: SE-18-EI-00825-DE
Closing Date: 10 September 2018




info

Information Technology Specialist (ENTARCH) Department of Energy - GS-14

Announcement Number: SE-18-EI-00825-MP
Closing Date: 10 September 2018




info

Information Technology Specialist (INFOSEC) - GS-2210-14

Announcement Number: SE-18-EI-00795-MP
Closing Date: 20 November 2017